Comprehensive assessment of the adherence to the head Y_x000D_ the status of the MUCOSA MEDIANING THE COMBINATED Analyses of Immunogenic PEPTIDs_x000D_ GLUTEN (GIP) and calprotection in other CELLIENT CAPITIES FEATURES (Q3169899)
Jump to navigation
Jump to search
Project Q3169899 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Comprehensive assessment of the adherence to the head Y_x000D_ the status of the MUCOSA MEDIANING THE COMBINATED Analyses of Immunogenic PEPTIDs_x000D_ GLUTEN (GIP) and calprotection in other CELLIENT CAPITIES FEATURES |
Project Q3169899 in Spain |
Statements
180,388.0 Euro
0 references
225,485.0 Euro
0 references
80.0 percent
0 references
3 November 2017
0 references
31 December 2019
0 references
BIOMEDAL, S.L.
0 references
37°24'7.24"N, 6°1'59.38"W
0 references
41021
0 references
La enfermedad celíaca (EC) es una enfermedad autoinmune caracterizada por una intolerancia permanente a las proteínas del gluten procedente del trigo, cebada, centeno y de algunas variedades de avena en individuos predispuestos genéticamente. Provoca atrofia de las vellosidades intestinales que llevan a malabsorción de nutrientes y a múltiples síntomas asociados como la diarrea, maltnutrición, anemia, depresión, dermatitis herpetiforme, alteración del carácter, entre otros. El único tratamiento efectivo que existe es seguir una estricta dieta sin gluten (DSG) de por vida. Sin embargo, una adherencia estricta a la DSG es difícil porque el gluten está presente en más del 50% de los productos manufacturados. Al menos un 43% de los celiacos con más de un año en DSG mantienen atrofia de las vellosidades intestinales, la principal consecuencia de la celiaquía sin controlar (Sharkey et al., 2013). _x000D_ _x000D_ El objetivo general de este proyecto es el desarrollo y validación de un test inmucromatográfico de flujo lateral que proporcione al paciente celíaco información específica de su adherencia a la DSG y del estado de su mucosa intestinal mediante el análisis combinado de GIP y calprotectina (CP) en heces._x000D_ _x000D_ La posibilidad de realizar un test doble de GIP y CP que evalúe el seguimiento de la DSG y el estado de la mucosa de forma indirecta podría ser la solución necesaria para la sustitución de la biopsia intestinal proporcionando una herramienta no intrusiva, mucho más barata y rápida, con el consiguiente ahorro en tiempo para el paciente y el médico y ahorro económico para los sistemas de salud. (Spanish)
0 references
Celiac disease (CED) is an autoimmune disease characterised by permanent intolerance to gluten proteins from wheat, barley, rye and some varieties of oats in genetically predisposed individuals. It causes atrophy of intestinal villi that lead to malabsorption of nutrients and multiple associated symptoms such as diarrhoea, maltnutrition, anemia, depression, herpetiforme dermatitis, alteration of character, among others. The only effective treatment that exists is to follow a strict gluten-free diet (DSG) for life. However, strict adherence to DSG is difficult because gluten is present in more than 50 % of manufactured products. At least 43 % of celiacs with more than one year in DSG maintain intestinal villi atrophy, the main consequence of uncontrolled celiac disease (Sharkey et al., 2013). _x000D_ _x000D_ the overall objective of this project is to develop and validate an immucromatographic lateral flow test that provides the celiac patient with specific information on their adherence to DSG and the status of their intestinal mucosa through the combined analysis of GIP and calprotectin (CP) in feces._x000D_ _x000D__x000D__x000D__x000D__x000D__x000D__x000D_ _x000D_ the overall objective of this project is the development and validation of an immucromatographic lateral flow test that provides the coeliac patient with specific information on their adherence to the DSG and the status of their intestinal mucosa through the combined analysis of GIP and calprotectin (CP) in feces._x000D__x000D__x000D__x000D_ The overall objective of this project is the development and validation of an immucromatographic lateral flow test that provides specific information to the celiac patient regarding their adherence to DSG and the status of their intestinal mucosa by combined analysis of GIP and calprotectin (CP) in feces._x000D__x000D__x000D__x000D__x000D__x000D__x000D__x000D__x000D_ the overall objective of this project is the development and validation of an immucromatographic lateral flow test that provides the celiac patient with specific information on their adherence to DSG and the status of their intestinal mucosa through the combined analysis of GIP and calprotectin (CP) in feces._x000D__x000D__x000D__x000D__x000D__x000D__x000D__x000D__x000D_ the overall objective of this project is to develop and (English)
12 October 2021
0 references
Camas
0 references
Identifiers
IDI-20180051
0 references